BRPI0800596A2 - método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer - Google Patents

método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer

Info

Publication number
BRPI0800596A2
BRPI0800596A2 BRPI0800596-6A BRPI0800596A BRPI0800596A2 BR PI0800596 A2 BRPI0800596 A2 BR PI0800596A2 BR PI0800596 A BRPI0800596 A BR PI0800596A BR PI0800596 A2 BRPI0800596 A2 BR PI0800596A2
Authority
BR
Brazil
Prior art keywords
toxin
pharmaceutical compositions
erectile function
potentiation
phoneutria nigriventer
Prior art date
Application number
BRPI0800596-6A
Other languages
English (en)
Inventor
Ruben Dario Sinisterra
Original Assignee
Univ Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais filed Critical Univ Minas Gerais
Priority to BRPI0800596-6A priority Critical patent/BRPI0800596A2/pt
Priority to CN2009801089005A priority patent/CN101981190A/zh
Priority to AU2009208322A priority patent/AU2009208322A1/en
Priority to EP09706043A priority patent/EP2247730A4/en
Priority to US12/865,818 priority patent/US20110236467A1/en
Priority to PCT/BR2009/000040 priority patent/WO2009094742A1/pt
Publication of BRPI0800596A2 publication Critical patent/BRPI0800596A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MéTODO PARA A POTENCIALIZAçãO DA FUNçãO ERéTIL ATRAVéS DO USO DAS COMPOSIçõES FARMACêUTICAS DE TOXINA Tx2-6 DA ARANHA PHONEUTRIA NIGRIVENTER. A presente invenção diz respeito a um método para a potencialização da função erétil masculina através do uso da toxina Tx2-6 da aranha Phoneutria nigriven ter.
BRPI0800596-6A 2008-01-31 2008-01-31 método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer BRPI0800596A2 (pt)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0800596-6A BRPI0800596A2 (pt) 2008-01-31 2008-01-31 método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer
CN2009801089005A CN101981190A (zh) 2008-01-31 2009-01-30 用于治疗勃起功能障碍的巴西漫游蜘蛛的毒素
AU2009208322A AU2009208322A1 (en) 2008-01-31 2009-01-30 Toxin of the spider Phoneutria nigriventer for treatment of erectile dysfunction
EP09706043A EP2247730A4 (en) 2008-01-31 2009-01-30 TOXIN OF THE SPIDER PHONEUTRIA NIGRIVENTER TO TREAT A POTENTIAL DISORDER
US12/865,818 US20110236467A1 (en) 2008-01-31 2009-01-30 Method for erectile function potentiation by pharmaceutical compositions comprising toxin tx2-6 of the spider phoneutria nigriventer
PCT/BR2009/000040 WO2009094742A1 (fr) 2008-01-31 2009-01-30 Toxine d'araignée de l'espèce phoneutria nigriventer destinée à traiter la dysfonction érectile

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0800596-6A BRPI0800596A2 (pt) 2008-01-31 2008-01-31 método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer

Publications (1)

Publication Number Publication Date
BRPI0800596A2 true BRPI0800596A2 (pt) 2009-09-22

Family

ID=40912189

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0800596-6A BRPI0800596A2 (pt) 2008-01-31 2008-01-31 método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer

Country Status (6)

Country Link
US (1) US20110236467A1 (pt)
EP (1) EP2247730A4 (pt)
CN (1) CN101981190A (pt)
AU (1) AU2009208322A1 (pt)
BR (1) BRPI0800596A2 (pt)
WO (1) WO2009094742A1 (pt)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028997A1 (pt) * 2012-08-20 2014-02-27 Universidade Federal De Minas Gerais - Ufmg Peptídeo sintético pntx(19), composições farmacêuticas e uso
WO2017068388A3 (pt) * 2015-09-18 2017-08-03 Universidade Federal De Minas Gerais - Ufmg Uso do peptideo sintetico pntx-19 para tratamento de dor
WO2020006617A1 (en) 2018-07-05 2020-01-09 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112603987B (zh) * 2021-01-07 2022-12-02 海南蛛王生物科技有限公司 一种治疗男性勃起障碍的贴剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK260782A (da) * 1981-06-12 1982-12-13 Nat Res Dev Hydrogeler
US5688499A (en) 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
US6365590B1 (en) 1998-05-26 2002-04-02 Saint Louis University Compounds, compositions and methods for treating erectile dysfunction
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6291471B1 (en) 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US7105571B2 (en) 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US7022728B2 (en) 2001-03-09 2006-04-04 Abbott Laboratories Benzimidazoles that are useful in treating male sexual dysfunction
BRPI0502411A (pt) * 2005-03-31 2006-11-28 Univ Minas Gerais processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028997A1 (pt) * 2012-08-20 2014-02-27 Universidade Federal De Minas Gerais - Ufmg Peptídeo sintético pntx(19), composições farmacêuticas e uso
US9279004B2 (en) 2012-08-20 2016-03-08 Universidade Federal De Minas Gerais—Ufmg Synthetic PnTx(19) peptide, pharmaceutical compositions and use
WO2017068388A3 (pt) * 2015-09-18 2017-08-03 Universidade Federal De Minas Gerais - Ufmg Uso do peptideo sintetico pntx-19 para tratamento de dor
WO2020006617A1 (en) 2018-07-05 2020-01-09 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses

Also Published As

Publication number Publication date
US20110236467A1 (en) 2011-09-29
CN101981190A (zh) 2011-02-23
EP2247730A4 (en) 2011-03-02
WO2009094742A8 (pt) 2009-12-03
EP2247730A1 (de) 2010-11-10
AU2009208322A1 (en) 2009-08-06
WO2009094742A9 (pt) 2009-09-24
WO2009094742A1 (fr) 2009-08-06

Similar Documents

Publication Publication Date Title
ECSP10010295A (es) Formulacion de anticuerpo
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
CR20110466A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
MX338712B (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
CR20110166A (es) Anticuerpos biespecíficos anti-vegf/anti-ang-2
UY34698A (es) Combinaciones farmacéuticas que comprenden un análogo de tionucleótidos
EA201001710A2 (ru) Фармацевтическая композиция, которая содержит соль стронция, витамин d и циклодекстрин
ECSP12011701A (es) Anticuerpos anti-cdcp1 humanizados
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
MX386584B (es) Composiciones de liberación retardada de linaclotida.
EA201600442A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
ES2408343R1 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
ECSP099561A (es) Formulación de nevirapina de liberación prolongada
ES2415029R1 (es) Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24.
ES2572368T3 (es) Tratamiento de la artrosis
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
BRPI0800596A2 (pt) método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements